Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | WRN | Q14191 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19545832 | 0.83 | GSK3A (0.47) | GSK3AGSK3BKDM4EMGLLALDH1A1 | |
| SCHEMBL29995038 | 0.82 | GSK3A (0.48) | GSK3AGSK3BKDM4EMGLLALDH1A1 | |
| SCHEMBL22281365 | 0.80 | GSK3A (0.47) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL836019 | 0.79 | PTGS1 (0.47) | GSK3AGSK3BPOLBMGLLALDH1A1 | |
| SCHEMBL3665093 | 0.79 | GSK3A (0.52) | GSK3AGSK3BKDM4EMGLLALDH1A1 | |
| SCHEMBL8738193 | 0.78 | GSK3A (0.46) | GSK3AGSK3BKDM4EMGLLALDH1A1 | |
| SCHEMBL7049984 | 0.78 | GSK3A (0.50) | GSK3AGSK3BKDM4EMGLLALDH1A1 | |
| SCHEMBL15386866 | 0.78 | KMT2A (0.56) | GSK3AGSK3BPOLBKDM4EMGLL | |
| SCHEMBL25699409 | 0.77 | GSK3A (0.42) | GSK3AGSK3BMGLLALDH1A1BLM | |
| SCHEMBL20287639 | 0.76 | GSK3A (0.44) | GSK3AGSK3BPOLBMGLLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036285-B2 | Immunogenic conjugates and use thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-16 | — | — | US | disclosed |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | disclosed |
| US-20230137821-A1 | IMMUNOGENIC CONJUGATES AND USE THEREOF | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2023-05-04 | — | — | US | disclosed |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10016512-B2 | Immobilised biological entities | CARMEDA AB (SE) | 2018-07-10 | — | — | US | disclosed |
| US-20180140713-A1 | IMMOBILISED BIOLOGICAL ENTITIES | CARMEDA AB (SE) | 2018-05-24 | — | — | US | disclosed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170368237-A1 | IMMOBILISED BIOLOGICAL ENTITIES | GORE & ASS (US) | 2017-12-28 | — | — | US | disclosed |
| EP-2143736-A1 | Hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2010-01-13 | — | — | EP | disclosed |
| US-20090317328-A1 | TRICYCLIC OXAZEPINES AS IN VIVO IMAGING COMPOUNDS | ARSTAD ERIK | 2009-12-24 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090181398-A1 | Nanoparticle conjugates | VENTANA MEDICAL SYSTEMS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090176253-A1 | Antibody conjugates | VENTANA MEDICAL SYSTEMS, INC. | 2009-07-09 | — | — | US | disclosed |
| EP-2017287-A2 | Method of producing hydroxyalkyl starch derivatives | Fresenius Kabi Deutschland GmbH (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| US-20080279765-A1 | Novel Imaging Agents for Fibrosis | CHETTIBI SALAH | 2008-11-13 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1398327-B1 | Method of producing hydroxyalkyl starch derivatives | FRESENIUS KABI DE GMBH (DE) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | GSK3A 2940/4885GSK3B 2797/4885POLB 3693/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | GSK3A 1917/4885GSK3B 1866/4885POLB 3921/4885 |
| US-20230137821-A1 | IMMUNOGENIC CONJUGATES AND USE THEREOF | VAPB, CHMP4B, CD14 | GSK3A 4767/4885GSK3B 4699/4885POLB 3969/4885 |
| US-20080279765-A1 | Novel Imaging Agents for Fibrosis | M6PR, IGF2R, MPI | GSK3A 2676/4885GSK3B 2386/4885POLB 4784/4885 |
| US-20230137914-A1 | nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF | VAPB, CD14, CHMP4B | GSK3A 4820/4885GSK3B 4759/4885POLB 3999/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | GSK3A 4103/4885GSK3B 3939/4885POLB 2322/4885 |
| US-20180140713-A1 | IMMOBILISED BIOLOGICAL ENTITIES | FGB, SELE, EPCAM | GSK3A 3514/4885GSK3B 3847/4885POLB 4441/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | GSK3A 333/4885GSK3B 229/4885POLB 4594/4885 |
| US-20090317328-A1 | TRICYCLIC OXAZEPINES AS IN VIVO IMAGING COMPOUNDS | CNR2, CNR1, OPRL1 | GSK3A 784/4885GSK3B 485/4885POLB 967/4885 |
| US-12036285-B2 | Immunogenic conjugates and use thereof | VAPB, CHMP4B, CD14 | GSK3A 4767/4885GSK3B 4699/4885POLB 3969/4885 |
| US-10016512-B2 | Immobilised biological entities | FGB, SELE, EPCAM | GSK3A 3514/4885GSK3B 3847/4885POLB 4441/4885 |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | LOXL1, LOXL2, LOXL3 | GSK3A 2451/4885GSK3B 2018/4885POLB 4032/4885 |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, AHR, RORB | GSK3A 1917/4885GSK3B 1866/4885POLB 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.